- Home
- ADN vs MEIP Comparison
ADN vs MEIP Comparison
Compare ADN & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADN
- MEIP
- Stock Information
- Founded
- ADN 2006
- MEIP 2000
- Country
- ADN United States
- MEIP United States
- Employees
- ADN N/A
- MEIP 28
- Industry
- ADN Power Generation
- MEIP Biotechnology: Pharmaceutical Preparations
- Sector
- ADN Utilities
- MEIP Health Care
- Exchange
- ADN Nasdaq
- MEIP Nasdaq
- Market Cap
- ADN 16.7M
- MEIP 17.3M
- IPO Year
- ADN N/A
- MEIP 2003
- Fundamental
- Price
- ADN $4.96
- MEIP $2.60
- Analyst Decision
- ADN
- MEIP Hold
- Analyst Count
- ADN 0
- MEIP 2
- Target Price
- ADN N/A
- MEIP $7.00
- AVG Volume (30 Days)
- ADN 12.2K
- MEIP 7.5K
- Earning Date
- ADN 12-27-2024
- MEIP 02-12-2025
- Dividend Yield
- ADN N/A
- MEIP N/A
- EPS Growth
- ADN N/A
- MEIP N/A
- EPS
- ADN N/A
- MEIP N/A
- Revenue
- ADN $8,157,000.00
- MEIP N/A
- Revenue This Year
- ADN $2,232.99
- MEIP N/A
- Revenue Next Year
- ADN $91.56
- MEIP N/A
- P/E Ratio
- ADN N/A
- MEIP N/A
- Revenue Growth
- ADN 274.35
- MEIP 33.76
- 52 Week Low
- ADN $1.71
- MEIP $2.30
- 52 Week High
- ADN $9.54
- MEIP $4.42
- Technical
- Relative Strength Index (RSI)
- ADN 44.58
- MEIP 37.79
- Support Level
- ADN $4.78
- MEIP $2.55
- Resistance Level
- ADN $5.50
- MEIP $2.79
- Average True Range (ATR)
- ADN 0.39
- MEIP 0.14
- MACD
- ADN 0.01
- MEIP -0.02
- Stochastic Oscillator
- ADN 50.91
- MEIP 14.71
About ADN Advent Technologies Holdings Inc.
Advent Technologies Holdings Inc is an innovation-driven company in the fuel cell and hydrogen technology space. The company develops, manufactures, and assembles complete fuel cell systems and the critical components that determine the performance of hydrogen fuel cells and other energy systems. It serves automotive; aviation and power generation industries. It generates revenue from the sale of fuel cell systems and the sale of MEAs, membranes, and electrodes for specific applications in the fuel cell and energy storage (flow battery) markets.
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.